Posters

Visual outcomes after bilateral Tecnis Eyhance implantation: 1 year follow-up

Poster Details

First Author: M.Belovari CROATIA

Co Author(s):    I. Krolo   B. Kuzmanovic Elabjer   D. Saric   D. Grgic   F. Drobec   M. Jelcic     

Abstract Details

Purpose:

To evaluate visual outcomes after bilateral Tecnis Eyhance intraocular lens (IOL) implantation in patients with cataracts who came to our clinic for a refractive solution, and were contraindicated for multifocal and/or extended depth od focus (EDOF) IOLs.

Setting:

Optical Express, Zagreb, Croatia

Methods:

In this prospective study 84 eyes of 42 patients were enrolled. Bilateral lens phacoemulsification with implantation of a monofocal Tecnis Eyhance IOL (Johnson & Johnson Vision) were performed by the same surgeon. Second eye was operated 1 month after the first eye. Visual outcomes, including uncorrected distance visual acuity(UCDVA), intermediate(UCIVA) and near(UCNVA) visual acuity, as well as corrected distance visual acuity(CDVA), distance-corrected intermediate(DCIVA) and distance-corrected near visual acuity(DCNVA), photic phenomena (halo and glare) and patient's satisfaction (Catquest-9SF2011) were assessed preoperatively and during the 1 year follow-up period. Exclusion criteria were moderate to severe forms of maculopathy, epiretinal membrane and amblyopia.

Results:

Data collected on 84 eyes marked that UCDVA and UCIVA achieved the satisfying visual outcomes 7 days following first eye surgery, and remained stable during 1 year follow up period. Improvement of UCIVA and more acceptable UCNVA occured 7 days after second eye surgery and also remained stable. Uncorrected bilateral visual acuity showed better spectacle independence than distance-corrected visual acuity at all 3 distances, also patients reported a high level of satisfaction and an absence of glare or halo 1 year postoperatively.

Conclusions:

In this study, the Tecnis Eyhance IOL provided excellent visual performance at distant and intermediate distances resulting in high levels of patients satisfaction and almost complete spectacle independence in patients with cataracts who were not suitable for other types of premium IOLs.

Financial Disclosure:

None